Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 23, 2026

Prediction: Nvidia Will Become the World's First $15 Trillion Company by 2029

View original at finance.yahoo.com
Prediction: Nvidia Will Become the World's First $15 Trillion Company by 2029 Nvidia(NASDAQ: NVDA) became the first company in the world to achieve a $5 trillion market capitalization in October 2025, fueled by the artificial intelligence (AI)-powered growth in its revenue and earnings in recent years…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nvidia will become the world's first $15 trillion company within the next three years (by approximately 2029)

    60% confidence
  • Nvidia's GPUs remain relevant and competitive in the AI inference era despite the preference shift toward custom chips

    60% confidence
  • Nvidia's non-GAAP earnings jumped 140% year over year to $1.87 per share in Q1 FY2027, up from 33% EPS growth in the year-ago period

    60% confidence
  • Nvidia anticipates $91 billion in revenue in Q2 FY2027, representing a 95% increase over the year-ago period

    60% confidence
  • An unnamed 'Indispensable Monopoly' company provides critical technology that both Nvidia and Intel require

    60% confidence
  • Hyperscalers and AI companies prefer custom chips in the inference era to reduce compute costs

    60% confidence
  • Nvidia reported 85% year-over-year revenue growth in Q1 FY2027 to $81.6 billion, significantly above the 69% growth in the same quarter last year

    60% confidence
  • GPUs are considered overkill for inference applications because inference workloads require much less computational power than training

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com